Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
NerveTrace Dx Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
NerveTrace Dx: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Mesenchymal Stem Cells Derived Exosomes(Isfahan University of Medical Sciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Mesenchymal Stem Cells Derived Exosomes(Isfahan University of Medical Sciences): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical develop
9 min read
BCMA CAR-T cells(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
BCMA CAR-T cells(Shenzhen Geno-Immune Medical Institute): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing dea
9 min read
Anti BCMA CAR-T Cell(Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Anti BCMA CAR-T Cell(Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers c
9 min read
ICP-B381 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ICP-B381: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(University of Manchester) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(University of Manchester): Phase 1/2. 2026 diligence verdict: HOLD / OPTION.
9 min read
BRT-OpCT-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
BRT-OpCT-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidenc
9 min read
Recombinant Human Follicle Stimulating Hormone Fc Fusion Protein(Guangzhou Unicohealth Biological Technology Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant Human Follicle Stimulating Hormone Fc Fusion Protein(Guangzhou Unicohealth Biological Technology Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Ev
9 min read
Personalized Synthetic Long Peptide Vaccine(Jaime Leandro Foundation for Therapeutic Cancer Vaccines) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Personalized Synthetic Long Peptide Vaccine(Jaime Leandro Foundation for Therapeutic Cancer Vaccines): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review c